Pharmaceutical & Biotech
Biosimilars Show Their Muscle as Emerging Pharmaceutical Phenomenon
Almost the same, but not quite--a biosimilar is just that, similar but not equal to an original biological drug. And the market is definitely worth watching. Industrial Info is tracking nearly $2 billion in related projects
Released Thursday, May 17, 2018
Researched by Industrial Info Resources (Sugar Land, Texas)--Almost the same, but not quite--a biosimilar is just that, similar but not equal to an original biological drug. Unlike generics, biological drugs are too complex be duplicated. And the market for biosimilars is definitely worth watching. Industrial Info is tracking nearly $2 billion worth of active biosimilar facility projects worldwide.
Top earners are starting to lose patent protection for their biosimilars just as the sector is gaining strength, with some reports indicating that it will top $25 billion by 2025. Big Pharma is following the "if you can't beat 'em, join 'em" doctrine, including such majors as Amgen, Merck and Pfizer, all of which have their own biosimilar versions of their own drugs.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Want More IIR News Intelligence?
Make us a Preferred Source on Google to see more of us when you search.
Add Us On GoogleAsk Us
Have a question for our staff?
Submit a question and one of our experts will be happy to assist you.
Forecasts & Analytical Solutions
Where global project and asset data meets advanced analytics for smarter market sizing and forecasting.
Explore Our SolutionsRelated Articles
-
Pharmaceutical Majors Cut Investments in GermanyJune 22, 2026
-
U.S. Seeks New Section 301 Tariffs in Forced Labor FlapJune 18, 2026
PECWeb Global Market Intelligence Platform
Identify opportunities, anticipate change, and execute with confidence. PECWeb connects the industrial intelligence you need, from projects and assets to operational events, all in one platform.
Discover PecwebIndustry Intel
-
2026 European Petroleum Refining Project OutlookPodcast Episode / Jun 26, 2026
-
Brazil: Efficiency, Innovation, and Opportunities in the Food & Beverage IndustryPodcast Episode / Jun 12, 2026
-
2026-2027 Investment Radar for Mexico, Central America & the CaribbeanPodcast Episode / May 29, 2026
-
Innovations Shaping the Next Era of Power GenerationPodcast Episode / May 22, 2026
-
The Role of Contract Manufacturing in Global Pharma GrowthPodcast Episode / May 8, 2026